Biltmore Family Office’s Novartis NVS Stock Holding History

Biltmore Family Office’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,369	Closed	-$645K	–	233
2021 Q4	$645K	Hold	7,369	–	–	0.12%	107
2021 Q3	$603K	Buy	7,369 +2,572	+54%	+$231K	0.15%	95
2021 Q2	$438K	Hold	4,797	–	–	0.12%	111
2021 Q1	$410K	Hold	4,797	–	–	0.13%	112
2020 Q4	$453K	Sell	4,797 -1,700	-26%	-$149K	0.14%	99
2020 Q3	$565K	Hold	6,497	–	–	0.32%	71
2020 Q2	$567K	Sell	6,497 -80	-1%	-$6.91K	0.34%	73
2020 Q1	$542K	Buy	6,577 +160	+2%	+$14.3K	0.36%	75
2019 Q4	$608K	Hold	6,417	–	–	0.24%	84
2019 Q3	$558K	Hold	6,417	–	–	0.24%	86
2019 Q2	$586K	Sell	6,417 -744	-10%	-$63K	0.32%	77
2019 Q1	$617K	Hold	7,161	–	–	0.31%	80
2018 Q4	$551K	Buy	7,161 +455	+7%	+$35.4K	0.31%	82
2018 Q3	$518K	Hold	6,706	–	–	0.25%	92
2018 Q2	$454K	Sell	6,706 -26	-0.4%	-$1.79K	0.23%	91
2018 Q1	$508K	Sell	6,732 -808	-11%	-$61.5K	0.23%	101
2017 Q4	$567K	Buy	+7,540	New	+$569K	0.26%	89

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Biltmore Family Office's NVS Position: Q1 2022 in Review

Biltmore Family Office sold out of Novartis (NVS) in Q1 2022, closing a stake of 7,369 shares — an estimated $645K sold.

Biltmore Family Office first reported a position in NVS in Q4 2017 and held it in 17 quarters. The position peaked at $645K in Q4 2021. 1,136 funds tracked by Wall St. Rank hold NVS as of Q1 2022.

Biltmore Family Office reported no remaining Novartis position as of Q1 2022 after selling out during the quarter.
Biltmore Family Office sold 7,369 Novartis shares in Q1 2022, an estimated $645K.
Biltmore Family Office first reported a position in Novartis in Q4 2017 and held it in 17 quarters.
Biltmore Family Office's Novartis position peaked at $645K in Q4 2021.
1,136 funds tracked by Wall St. Rank held Novartis as of Q1 2022.

Based on Biltmore Family Office's 13F filing for Q1 2022, filed 12 May 2022.